Satellite Symposia
| Gilead | 15:45-17:45 26 March, Auditorium, Level 4 |
| Integration of Prevention and Medical Care for Hepatitis Elimination | |
| Chairs | Lai WEI, Beijing; Yu WANG, Beijing |
| Speakers | Gang CUI, Beijing; Sung Won LEE, Seoul; Jinlin HOU, Guangzhou; Jeremy LIM, Singapore; Zhongfu LIU, Beijing; Zengde LI, Beijing; Xiaoping TANG, Guangzhou; John WARD, Decatur; Jidong JIA, Beijing; Calvin Q. PAN, New York; Yasuhito TANAKA, Kumamoto; Lung Yi Mak, Hong Kong; Yoon Jun Kim, Seoul (Guests are listed by speaking order) |
| Amoytop | 08:00 - 08:30 28 March, Plenary Hall A, Level 4 |
| Peginterferon Alpha-2b (Mipeginterferon alfa-2b, Pegbing®) Promotes Durable Functional Cure in Patients with Chronic Hepatitis B: a Multicenter, Randomized Controlled, Phase 3 Trial and its Long-term Follow-up Study | |
| Chair | Jidong JIA, Beijing |
| Speaker | Guiqiang WANG, Beijing |
| 08:30 - 09:00 28 March, Plenary Hall A, Level 4 | |
| Progress and Achievements of the Everest Project for Functional Cure of Chronic Hepatitis B in China | |
| Chair | Zhiliang GAO, Guangzhou |
| Speaker | Chan XIE, Guangzhou |
| GSK | 12:00 - 13:00 28 March, Plenary Hall A, Level 4 |
| Destination Functional Cure in CHB: Are we there yet? | |
| Chair | Lai WEI, Beijing |
| Speakers | Grace WONG, Hong Kong; Wenhong ZHANG, Shanghai; Ed GANE, Auckland |
| Opella | 12:00 - 13:00 28 March, Function Hall A, Level 1 |
| MASLD: Early Screening, Treatment Strategies, and Quality of Life - Insights From New Clinical Evidence | |
| Chair | Zobair M. YOUNOSSI, Virginia |
| Speakers | Jiangao FAN, Shanghai; Norbert STEFAN, Tübingen; Jose D. SOLLANO, Manila |
| Grifols | 12:00 – 13:00 28 March, Function Hall B, Level 1 |
| Optimizing Treatment of Patients with Cirrhosis Using Albumin | |
| Chair | Huiguo DING, Beijing |
| Speakers | Bo FENG, Beijing; Rongqi WANG, Shijiazhuang |
| Novo Nordisk | 12:00 – 13:00 28 March, Function Hall C, Level 1 |
| Act Now: Implementing a Multidisciplinary Approach to MASLD Management | |
| Chairs | Yimin MAO, Shanghai; Lixin GUO, Beijing |
| Speakers | Huiying RAO, Beijing; Yingying LUO, Beijing |
| Abbott | 12:00 - 12:30 28 March, 401, Level 4 |
| Innovative Solution Supporting HCC Early Diagnosis and Enhancing Clinical Benefits: New Practice from China | |
| Chair | Tian YANG, Shanghai |
| Speaker | Jingyu CAO, Qingdao |
| 12:30 - 13:00 28 March, 401, Level 4 | |
| CHB Functional Cure: A New Era of Precision Diagnosis and Treatment | |
| Chair | Zhiliang GAO, Guangzhou |
| Speaker | Sujun ZHENG, Beijing |
| Furui | 12:00 -13:00 28 March, 403, Level 4 |
| Managed Care Reformulates Comprehensive Liver Health Management Paradigm | |
| Chairs | Xiaoyuan XU, Beijing; Yuemin NAN, Shijiazhuang |
| Speakers | Bingliang LIN, Guangzhou; Yongping CHEN, Wenzhou; Enqiang CHEN, Chengdu |
| Orphalan | 12:00 -13:00 28 March, 405, Level 4 |
| New Development in Wilson's Disease Management - APASL/AASLD Guidelines and Clinical Experience Sharing | |
| Chair | Jidong JIA, Beijing |
| Speakers | Wei ZHANG, Beijing; Robert G. GISH, San Diego |
| Viatris | 12:00 -13:00 28 March, 406, Level 4 |
| Updates in the Treatment of MAFLD: Integrative Approaches and Clinical Outcomes with Silymarin | |
| Chair | Xiaoyuan XU, Beijing |
| Speakers | Xiong MA, Shanghai; Sakkarin CHIRAPONGSATHORN, Bangkok; Lee Ling LIM, Kuala Lumpur |
| 3SBIO | 12:00 -13:00 28 March, 407, Level 4 |
| Clinical Management Symposium on Thrombocytopenia in Liver Disease | |
| Chairs | Xiaoyuan XU, Beijing; Yuemin NAN, Shijiazhuang |
| Speakers | Hong YOU, Beijing; Yan HUANG, Changsha |
| GSK | 16:45 - 17:45 28 March, Function Hall A, Level 1 |
| Destination Functional Cure in CHB: Can Innovative Mechanisms Overcome Roadblocks? | |
| Chair | Jinlin HOU, Guangzhou |
| Speakers | Yasuhito TANAKA, Kumamoto; Hong YOU, Beijing |
| Gilead | 16:45 - 17:45 28 March, Function Hall B, Level 1 |
| Ride the Trend: China Guideline For Viral Hepatitis Elimination | |
| Chair | Lai Wei, Beijing |
| Speakers | Peng HU, Chongqing; Liang PENG, Guangzhou |
| Gilead | 12:15 - 13:15 29 March, Plenary Hall A, Level 4 |
| Ride the Tide: The Future of Viral Hepatitis is Now | |
| Chair | Jidong JIA, Beijing |
| Speakers | Yuemin NAN, Shijiazhuang; Yasuhito TANAKA, Kumamoto; Chari COHEN, Doylestown |
| Hansoh | 12:15 - 13:15 29 March, Function Hall A, Level 1 |
| Symposium on Innovative Nucleotide-Based Therapeutics | |
| Chair | Jinlin HOU, Guangzhou |
| Speakers | Xiaoguang DOU, Shenyang; Zhihong LIU, Guangzhou; Qing XIE, Shanghai |
| Lilly | 12:15 - 13:15 29 March, Function Hall B, Level 1 |
| NIT Application in Phase 3 Clinical Trials for MAFLD/MASH Drug Development | |
| Chairs | Minghua ZHENG, Wenzhou |
| Speaker | Junping SHI, Hangzhou |
| Hisky / Hotgen / Viatris | 12:15 - 13:15 29 March, Auditorium, Level 4 |
| Precision Diagnosis and Treatment of MASH: Technological Innovation and Practical Exploration | |
| Chairs | Robert G. GISH, San Diego; Jiangao FAN, Shanghai |
| Speakers | Wei AN, Beijing; Hong YOU, Beijing; Li LI, Beijing; Jie LI, Nanjing; Rinaldi LESMANA, Jakarta; Graciela CASTRO, Mexico City |
| Roche Diagnostics | 12:15 - 13:15 29 March, 401, Level 4 |
| Total Management Solution for Liver Disease | |
| Chair | Xinxin ZHANG, Shanghai |
| Speakers | Wen XIE, Beijing; Qingxian CAI, Shenzhen |
| Brii Biosciences | 12:15 - 13:15 29 March, 402(A+B), Level 4 |
| Harnessing the Immune System – Novel Approaches in HBV Cure | |
| Host | David MARGOLIS, Durham |
| Speakers | Man-Fung YUEN, Hong Kong; Antonio BERTOLETTI, Singapore; Jinlin HOU, Guangzhou |
| Kawin | 12:15 - 13:15 29 March, 403, Level 4 |
| Symposium on Hepatitis C: Advances in Diagnosis, Treatment, and Public Health Control Strategies | |
| Co-Chairs | Lai WEI, Beijing; Hong TANG, Chengdu; Zhongfu LIU, Beijing |
| Speakers | Qing XIE, Shanghai; Mingyang LI, Beijing; Jing ZHANG, Beijing |
| Abbott | 12:15 - 13:15 29 March, 405, Level 4 |
| Intrahepatic Cholestasis Diagnosis and Treatment | |
| Chair | Xiaoyuan XU, Beijing |
| Speakers | Jose MATO, Derio; Lungen LU, Shanghai |
| Sanhome | 12:15 - 13:15 29 March, 406, Level 4 |
| The Epidemiology of Hepatitis C and the Latest Advances in Prevention and Treatment | |
| Chair | Yanhang GAO, Changchun; Chao WU, Nanjing; Qing XIE, Shanghai |
| Speakers | Huiying RAO, Beijing; Jian LI, Beijing; Junqi NIU, Changchun |
| HEC-Sunshine Lake Pharma | 17:00 - 18:00 29 March, Function Hall A, Level 1 |
| Symposium: Helping to Eliminate Hepatitis C Virus by 2030 | |
| Chair | Yuemin NAN, Shijiazhuang |
| Speakers | Xiaoping WU, Nanchang; Jiangbin WANG, Jilin |
| GSK | 17:00 - 18:00 29 March, Function Hall B, Level 1 |
| Advancing the Functional Cure of CHB in China: Overcoming Challenges, Embracing the Future | |
| Chair | Jinlin HOU, Guangzhou |
| Speakers | Junqi NIU, Changchun; Huiying RAO, Beijing |